Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
From BioCentury This Week · · 37 min
This plays from the publisher's own server. We do not host a copy.
Description
Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy (https://www.biocentury.com/article/660896) from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing (https://www.biocentury.com/article/660917) and lingering questions about her independence, new pharma tariff guidance that leaves exemptions unclear, and how reverse mergers (https://www.biocentury.com/article/660906) paired with nine-figure PIPEs became a viable IPO alternative. Plus, Merck's $400 million upfront bet on a preclinical KRAS G12C molecular glue.
View full story: https://www.biocentury.com/article/660935
#IgANephropathy #FDA #BiotechIPO #DrugDevelopment #ClinicalTrials
0:00 Introduction 1:30 Grand Rounds: Europe Recap 6:03 IgA Nephropathy Pipeline 14:57 Overton Hearing 22:19 Commerce's Tariff Guidance 24:28 Reverse Mergers' New Look
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)